mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Myosin wins $2M grant to advance brain cancer treatment MT-125

Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in glioblastoma, an aggressive form of glioma. The Florida Department of Health is providing the funds through the...

Overt forms advisory board to guide ovarian cancer therapy push

Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer, and other programs in its pipeline. The company said the newly formed advisory board will provide strategic...

Enhanced dynamic risk stratification of smoldering multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More
Latest Data

Latest Publications

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia

Cancer Treat Res Commun. 2026 Feb 28;47:101161. doi: 10.1016/j.ctarc.2026.101161. Online ahead of...

Assessment tools for peripheral neuropathy in multiple myeloma

Korean J Intern Med. 2026 Mar;41(2):230-241. doi: 10.3904/kjim.2025.281. Epub 2026 Mar 1. ABSTRACT...

Early intervention for high-risk smoldering multiple myeloma (SMM)

Cochrane Database Syst Rev. 2026 Mar 18;3:CD015494. doi: 10.1002/14651858.CD015494.pub2. ABSTRACT...

Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis

Ann Med. 2026 Dec;58(1):2641930. doi: 10.1080/07853890.2026.2641930. Epub 2026 Mar 12. ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet